查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1540932

2024-2032 年葡萄膜炎治療市場報告（依治療類型、疾病類型、病因、配銷通路和地區）

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球葡萄膜炎治療市場規模達17億美元。由於葡萄膜炎發病率上升、各種生物製劑和免疫抑制治療的持續研發活動以使治療可能性多樣化、更加重視提高認知和早期診斷、有利的政府政策和醫療保健報銷，市場正在經歷顯著成長。

葡萄膜炎治療市場分析：

主要市場促進因素：葡萄膜炎治療市場主要受到全球自體免疫疾病和發炎性疾病發生率上升的推動。由於它經常導致葡萄膜炎，因此越來越多的人需要藥物來減輕發炎並保護眼睛免於進一步惡化，從而促進市場成長。

主要市場趨勢：葡萄膜炎治療市場的主要趨勢包括迅速轉向使用生物製劑和標靶療法來治療葡萄膜炎。與傳統療法相比，這些療法表現出對目標行動的更深入理解，甚至可能更少程度地產生不良後果。此外，葡萄膜炎藥物輸送方法的改進，例如緩釋植入物，在葡萄膜炎的治療中提供了更好的效果，並提高了患者的依從性。

地理趨勢：北美佔據葡萄膜炎治療市場的最大佔有率。這得益於該地區發達的醫療保健系統、堅持早期使用新興療法以及對研發的大量投資。臨床試驗中主要市場參與者和學術機構中心的存在支持北美在葡萄膜炎更好的治療進展方面處於領先地位。

競爭格局：葡萄膜炎治療產業的一些主要市場參與者包括AbbVie Inc.、Alimera Sciences Inc.、Bausch & Lomb Incorporated (Bausch Health)、Enzo Biochem Inc.、Eyegate Pharmaceuticals Inc.、Eyepoint Pharmaceuticals Inc.、Novartis AGAG 、Regeneron Pharmaceuticals Inc.、參天製藥有限公司等。

挑戰與機會：葡萄膜炎治療市場的成長面臨著治療成本高、用於治療疾病的藥品核准過程複雜等挑戰。然而，機會在於醫療供應，特別是在快速成長的經濟體中，以及為葡萄膜炎患者開發新治療方法的持續研究。

葡萄膜炎治療市場趨勢：

自體免疫疾病的盛行率不斷增加

全球自體免疫疾病發生率的增加刺激了葡萄膜炎治療的需求。根據美國國立衛生研究院 (NIH) 報告，自體免疫疾病估計影響 2,350 萬美國人，他們患有類風濕性關節炎、發炎性腸道疾病和狼瘡等疾病，並繼發葡萄膜炎。值得注意的是，這種流行證明了對針對自體免疫疾病的有效葡萄膜炎療法的高需求並刺激了市場需求。因此，隨著這些疾病在世界各地的流行，治療的目標是葡萄膜炎及其控制症狀的療法，並解決導致疾病在患者生活中取得更好結果的自身免疫過程。

生物製劑和免疫療法的進展

生物製劑和免疫調節療法透過調節免疫介導的過程徹底改變了葡萄膜炎的治療。美國國立衛生研究院 (NIH) 已批准多種用於治療葡萄膜炎等自體免疫疾病的生物製劑，這標誌著人們開始轉向使用經濟有效的生物製劑。與皮質類固醇等其他治療方法相比，此類療法具有較低的副作用影響身體其他器官的可能性，這反過來又見證了患者更願意接受向他們推薦的治療方案。因此，生物技術和免疫學市場持續存在，導致生物製劑和免疫調節劑的產品開發，擴大了全球市場葡萄膜炎治療的機會。

醫療保健支出和研究經費不斷增加

政府在醫療保健系統、發展策略和醫療保健進步方面支出的增加正在推動葡萄膜炎治療的市場價值。在美國，美國國立衛生研究院 (NIH) 支持大量資金來研究葡萄膜炎和其他自體免疫疾病，這項研究是大學、製藥業和醫院之間的多部門、多方合作。這種財政支持進一步為葡萄膜炎新療法的進展帶來積極的變化，推動新藥、生物製劑和治療方法的開發。此外，政府支持的研究撥款和臨床試驗提供了必要的框架和資源，以支持探索新的治療方案並驗證治療的有效性。這些動態使得葡萄膜炎治療市場高度研究密集，因為它利用將發現轉化為臨床有用的產品和服務，滿足現有需求並增強全球患者的體驗。

葡萄膜炎治療市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據治療類型、疾病類型、病因和配銷通路對市場進行了分類。

按治療類型細分：

皮質類固醇

免疫抑制劑

單株抗體

睫狀肌麻痺劑

抗生素

抗病毒藥

抗真菌劑

止痛藥

皮質類固醇佔大部分市場佔有率

該報告根據治療類型對市場進行了詳細的細分和分析。這包括皮質類固醇、免疫抑制劑、單株抗體、睫狀肌麻痺劑、抗生素、抗病毒藥、抗黴菌藥和止痛藥。根據該報告，皮質類固醇佔最大部分。

根據葡萄膜炎治療市場預測，皮質類固醇在葡萄膜炎治療市場中佔據主導地位，因為它們有助於減少受影響個體的發炎並保持視力。美國國立衛生研究院(NIH) 報告稱，皮質類固醇是葡萄膜炎的主要治療方法，因為它們可以快速控制發炎和不同葡萄膜炎類型（前葡萄膜炎、後葡萄膜炎和全葡萄膜炎）的體徵。這些藥物的主要適應症是降低身體抵抗眼部感染的能力並減少炎症，從而提供快速有效的緩解並提高患者的健康程度。根據病情的嚴重程度和患者的病情，可以透過眼藥水、注射劑和口服片劑給予皮質類固醇。由於皮質類固醇可能存在副作用，包括長期使用導致眼壓升高和術後白內障形成，因此它們仍然優於其他競爭對手，而中等有效的局部非類固醇抗發炎藥物在葡萄膜炎治療中並不那麼受歡迎，儘管在眼科實踐中經常使用。

按疾病類型細分：

前葡萄膜炎

後葡萄膜炎

中間葡萄膜炎

全葡萄膜炎

前葡萄膜炎產業佔最大

報告還根據疾病類型對市場進行了詳細的細分和分析。這包括前葡萄膜炎、後葡萄膜炎、中間葡萄膜炎和全葡萄膜炎。報告稱，前葡萄膜炎佔最大的市場佔有率。

前葡萄膜炎因其發病率較高且需要獨特的治療方法而在葡萄膜炎治療細分領域佔據領先地位。美國國立衛生研究院 (NIH) 將前葡萄膜炎歸類為最常見的葡萄膜炎類型，占美國報告的所有葡萄膜炎的 50-60%。這是由眼睛前部（稱為葡萄膜）的結構性發炎引起的，它與自體免疫疾病、感染或身體損傷有關。因此，這種模式意味著前葡萄膜炎的治療需要不同的管理策略，例如局部皮質類固醇和擴瞳劑，在診所或眼科和零售店進行常規管理，從而創造有利的治療效果

分手原因：

傳染性

非傳染性

非感染性代表領先的細分市場

該報告根據原因對市場進行了詳細的細分和分析。這包括傳染性和非傳染性。根據該報告，非傳染性佔最大部分。

非感染性葡萄膜炎治療市場收入成長，因為這種疾病比感染相關的疾病更常見，並且透過改進針對自體免疫和發炎過程的實證個體化治療來解決。根據美國國立衛生研究院 (NIH) 的數據，在美國，非感染性葡萄膜炎約佔所有葡萄膜炎病例的 80-90%。這種形式的葡萄膜炎與類風濕性關節炎、發炎性腸道疾病、狼瘡等自體免疫疾病更相關，並且需要生物製劑和免疫調節劑。世界各地的研究人員觀察到，自體免疫疾病的病例不斷增加，這加強了非感染性葡萄膜炎治療的市場地位。現代製藥業專注於開發適當的個人化抗視網膜製劑，以更有效地針對非感染性葡萄膜炎的免疫致病背景，同時將全身給藥的副作用降至最低，從而創造良好的葡萄膜炎治療市場前景。

按配銷通路分類：

醫院藥房

零售藥局

網路藥局

其他

零售藥局在市場上表現出明顯的主導地位

報告還提供了基於配銷通路的詳細市場細分和分析。這包括醫院藥房、零售藥房、線上藥房等。報告顯示，零售藥局佔據了最大的市場佔有率。

零售藥局在葡萄膜炎治療中佔有最大的市場佔有率，主要是因為它們容易取得、方便，尤其是對患者而言，而且它們也從事藥物配發。美國社區藥劑師協會 (NCPA) 報告稱，美國約 72% 的處方是由零售藥房配發的，這強調了藥劑師在配藥過程中的中心地位。葡萄膜炎治療市場概況表明，被診斷為葡萄膜炎的患者可以方便且快速地從零售藥房獲得處方藥，如皮質類固醇、免疫抑制劑和生物製劑。此外，零售藥局還涉及患者諮詢、藥物和健康保險資訊及管理，從而提高患者滿意度和治療效果。利害關係人使用它們與衛生系統和電子健康記錄進行交互，從而為葡萄膜炎患者提供連續性護理。由於零售藥房的服務日益多樣化以及對患者和消費者的關注日益深入，它們為滿足葡萄膜炎藥物市場日益成長的需求做出了巨大貢獻，並主導了藥物的分銷。

按地區分類：

北美洲

美國

加拿大

亞太地區

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔最大的葡萄膜炎治療市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）、亞太地區（中國、日本、印度、韓國、澳洲、印尼等）、歐洲（德國） 、法國、英國、義大利、西班牙、俄羅斯等）、拉丁美洲（巴西、墨西哥等）以及中東和非洲。報告稱，北美是葡萄膜炎治療的最大區域市場。

根據葡萄膜炎治療市場報告，北美因其發達和先進的醫療保健行業、接受新穎的治療管理以及直接的研發支出而佔據最大的市場佔有率。根據美國國立衛生研究院 (NIH) 報告，僅在美國就有大量預算專門用於自體免疫疾病研究，並且各製藥實體、研究機構和護理人員之間存在有利於大量臨床試驗和合作的環境。這種策略性投資使北美國家能夠在生物製劑、免疫調節劑和其他葡萄膜炎治療方法的開發和商業化方面處於領先地位。此外，由於自體免疫疾病後來發展為葡萄膜炎的頻率較高，北美地區需要有效的葡萄膜炎治療和管理，以維持全球葡萄膜炎市場的市場領導地位。

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。葡萄膜炎治療產業的一些主要市場參與者包括 AbbVie Inc.、Alimera Sciences Inc.、Bausch & Lomb Incorporated (Bausch Health)、Enzo Biochem Inc.、Eyegate Pharmaceuticals Inc.、Eyepoint Pharmaceuticals Inc.、Novartis AG、Regeneron Pharmaceuticals株式會社、參天製藥株式會社

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

葡萄膜炎治療公司包括製藥公司和研究機構都專注於葡萄膜炎治療的發展，透過臨床試驗來應對葡萄膜炎疾病過程中提出的各種挑戰。艾伯維 (AbbVie)、諾華 (Novartis) 和艾爾建 (Allergan) 等市場領導者致力於研發推出針對葡萄膜炎發展的特定免疫過程的新藥。例如，艾伯維（AbbVie）的研究策略涉及最近的合作和臨床試驗，探索生物製劑在自體免疫性葡萄膜炎中的應用，證明了對精準醫療的關注。其中許多活動都是透過政府和研究資助來資助的，這些資助促進了學術與產業的合作，以在葡萄膜炎治療範式轉變的背景下推進治療進展並改善患者的護理，從而推動葡萄膜炎治療行業的成長。

葡萄膜炎治療市場新聞：

2024 年 4 月，Brepocitinib 在一項 2 期研究中顯示出治療非感染性葡萄膜炎的正面結果，顯示出在減少發炎和改善患者預後方面的良好療效。

本報告回答的關鍵問題

  • 2023年全球葡萄膜炎治療市場規模是多少
  • 2024-2032年全球葡萄膜炎治療市場的預期成長率是多少
  • COVID-19 對全球葡萄膜炎治療市場有何影響
  • 推動全球葡萄膜炎治療市場的關鍵因素是什麼
  • 根據治療類型，全球葡萄膜炎治療市場的細分如何
  • 根據疾病類型，全球葡萄膜炎治療市場的細分如何
  • 全球葡萄膜炎治療市場的分裂原因是什麼
  • 基於配銷通路的全球葡萄膜炎治療市場的細分是什麼
  • 全球葡萄膜炎治療市場的重點區域有哪些
  • 10. 全球葡萄膜炎治療市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 2023年全球葡萄膜炎治療市場規模有多大？ 2024-2032年全球葡萄膜炎治療市場的預期成長率是多少？
  • COVID-19 對全球葡萄膜炎治療市場有何影響？
  • 推動全球葡萄膜炎治療市場的關鍵因素是什麼？
  • 根據治療類型，全球葡萄膜炎治療市場的詳細情形如何？
  • 根據疾病類型，全球葡萄膜炎治療市場的詳細情形如何？
  • 全球葡萄膜炎治療市場的分裂原因是什麼？
  • 根據配銷通路，全球葡萄膜炎治療市場的詳細情形如何？
  • 全球葡萄膜炎治療市場的關鍵地區有哪些？
  • 全球葡萄膜炎治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球葡萄膜炎治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類型

  • 皮質類固醇
    • 市場趨勢
    • 市場預測
  • 免疫抑制劑
    • 市場趨勢
    • 市場預測
  • 單株抗體
    • 市場趨勢
    • 市場預測
  • 睫狀肌麻痺劑
    • 市場趨勢
    • 市場預測
  • 抗生素
    • 市場趨勢
    • 市場預測
  • 抗病毒藥
    • 市場趨勢
    • 市場預測
  • 抗真菌劑
    • 市場趨勢
    • 市場預測
  • 止痛藥
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依疾病類型

  • 前葡萄膜炎
    • 市場趨勢
    • 市場預測
  • 後葡萄膜炎
    • 市場趨勢
    • 市場預測
  • 中間葡萄膜炎
    • 市場趨勢
    • 市場預測
  • 全葡萄膜炎
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按原因

  • 傳染性
    • 市場趨勢
    • 市場預測
  • 非傳染性
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 零售藥局
    • 市場趨勢
    • 市場預測
  • 網路藥局
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Alimera Sciences Inc.
    • Bausch & Lomb Incorporated (Bausch Health)
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals Inc.
    • Eyepoint pharmaceuticals Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co. Ltd.
Product Code: SR112024A2759

The global uveitis treatment market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032. The market is experiencing significant growth driven by the rising incidence of uveitis, ongoing research and development activities in various biologics and immunosuppressive treatments to diversify treatment possibilities, heightening emphasis on increasing awareness and early diagnosis, favorable government policies, and healthcare reimbursements.

Uveitis Treatment Market Analysis:

Major Market Drivers: The uveitis treatment market is primarily driven by the rising rates of autoimmune disorders and inflammatory illnesses globally. Since it results in uveitis often, there is increasing incidences of people in need of medication that can reduce inflammation and protect the eyes from further deterioration, thus contributing to market growth.

Key Market Trends: The key uveitis treatment market trends include a rapid shift toward the use of biologics and targeted therapies for the management of uveitis. In comparison to the conventional treatments, these therapies demonstrate a closer understanding of the targeted actions and possibly even less levels of undesired consequences. Further, improved methods of drug delivery in uveitis such as sustained-release implants are providing better results in the therapy of uveitis and higher patient compliance.

Geographical Trends: North America holds the largest share of the uveitis treatment market. This is due to the region's well-developed health care system, the insistence of the early use of emerging treatments, and large investments in research and development. The existence of hubs of key market players and academic institutions in clinical trials supports North America as a lead in the progress of better treatments for uveitis.

Competitive Landscape: Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., among many others.

Challenges and Opportunities: The uveitis treatment market growth faces challenges such as high costs of treatment and complicated procedures for approval of drugs used for the treatment of the condition. However, the opportunities lie in the medical provisions, especially in the fast-growing economies and in the continual research to develop new treatment methods for uveitis patients.

Uveitis Treatment Market Trends:

Increasing Prevalence of Autoimmune Diseases

The uveitis treatment demand is stimulated by the increased rate of autoimmune diseases all over the world. As reported by the National Institutes of Health (NIH), autoimmune diseases are estimated to affect 23.5 million Americans, who have rheumatoid arthritis, inflammatory bowel disease, and lupus among other diseases develop uveitis as a sequel. It is important to note that this prevalence proves the high requirement for efficient uveitis therapies targeted at autoimmune diseases and stimulating the demand in the market. Thus, as these diseases move high across the world, treatment aims for uveitis and its therapies controlling the symptoms and it addresses the autoimmune processes that cause the disease to achieve better results in patients' lives.

Advancements in Biologics and Immunotherapy Therapies

Biologics and immunomodulatory therapies have revolutionized uveitis management by modulation of immune-mediated processes. The National Institutes of Health (NIH) has approved various biologics for autoimmune diseases, such as uveitis, signifying the change towards the use of cost-effective and effective biologics. Such therapies have benefits such as lower probability of side effects affecting other organs in the body than other treatments like corticosteroids which in turn is witnessing patients being more compliant to the treatment regimens that are recommended to them. As a result, there are continued markets in biotechnology and immunology leading to product development in biologics and immunomodulators extending the opportunities for the treatment of uveitis in the global market.

Rising Healthcare Expenditure and Research Funding

Increased government spending in healthcare systems, development strategies, and advances in healthcare are fueling the uveitis treatment market value. In the USA, the NIH supports significant funding to investigate uveitis and other auto-immune disorders, and this research has been a multisectoral and multiparty cooperation among universities, pharmaceutical industries, and hospitals. This financial support further brings a positive change to the progression of new treatments for uveitis as it pushes the development of new drugs, biologics, and treatment methods. Moreover, research grants and clinical trials that are supported by the government offer essential frameworks and resources to support the exploration of novel therapeutic profiles and verify the effectiveness of treatments. These dynamics make the uveitis treatment market highly research-intensive, as it capitalizes on the conversion of discoveries into clinically useful products and services that address existing requirements and enhance patient experience worldwide.

Uveitis Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on treatment type, disease type, cause, and distribution channel.

Breakup by Treatment Type:

Corticosteroids

Immunosuppressant

Monoclonal Antibodies

Cycloplegic Agents

Antibiotics

Antivirals

Antifungal

Analgesics

Corticosteroids account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics. According to the report, corticosteroids represented the largest segment.

As per the uveitis treatment market forecast, Corticosteroids thus dominate the uveitis treatment market by share since they help reduce inflammation and maintain vision in affected individuals. The National Institutes of Health (NIH) reported that corticosteroids are the primary therapy for uveitis, as they yield fast control of inflammation and signs about different uveitis types, anterior, posterior, and panuveitis. The main indications for these medicines are to lessen the body's ability to fight infection in the eye and diminish inflammation, which provides fast and effective relief and enhances the degree of patient's health. Corticosteroids can be administered through eye drops, injections, and oral tablets depending on the intensity of the situation and condition of the patient. As corticosteroids present possible side-effects, including rising intraocular pressure and postoperative cataract formation by long-term application, they remain preferred to other competitors while moderately effective topical NSAIDs are not as popular in uveitis treatment despite frequent use in ophthalmological practice.

Breakup by Disease Type:

Anterior Uveitis

Posterior Uveitis

Intermediate Uveitis

Panuveitis

Anterior uveitis holds the largest share of the industry

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. According to the report, anterior uveitis accounted for the largest market share.

Anterior uveitis holds a leading position in the segmentation of uveitis treatment because of its greater incidence and the necessity of unique therapy. The National Institutes of Health (NIH) categorizes anterior uveitis as the most prevalent type of uveitis which accounts for 50-60% of all uveitis reported in the United States. This is caused by inflammation of the structures of the anterior part of the eye known as the uvea, it is linked with autoimmune diseases, infections, or physical injury. As a result, the pattern implies the treatment of anterior uveitis requires different management strategies such as topical corticosteroids and pupil-dilating agents available, routinely managed in clinics or ophthalmology and retail outlets, thus creating a favorable

Breakup by Cause:

Infectious

Non-infectious

Non-infectious represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the cause. This includes infectious and non-infectious. According to the report, non-infectious represented the largest segment.

Non-infectious drive the uveitis treatment market revenue as the condition is more frequent than the infection-related kind and was addressed using improving evidence-based individualized treatment targeting autoimmune and inflammation processes. According to the National Institutes of Health (NIH), non-infectious uveitis accounts for approximately 80-90% of all uveitis cases in the United States. This form of uveitis is more related to autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, lupus, and the need for biologics and immunomodulatory agents. It has been observed by researchers from across the world that the cases of autoimmune diseases are continuously increasing, which strengthens the market position of the non-infectious forms of uveitis treatments. The modern pharmaceutical industry concentrates on the development of proper individual antiretirologic preparations to target more effectively the immunopathogenetic background of non-infectious uveitis with minimal side effects from systemic administration, thus creating a favorable uveitis treatment market outlook.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Retail pharmacies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, retail pharmacies accounted for the largest market share.

Retail pharmacies hold the largest market share of uveitis treatment primarily because they are easily accessible, and convenient, especially to the patients and they also engage in the dispensing of drugs. The National Community Pharmacists Association (NCPA) repoted that retail pharmacies in the United States dispense about 72% of prescriptions emphasizing the centrality of pharmacists in dispensing of medication. This uveitis treatment market overview shows that patients diagnosed with uveitis can conveniently get prescribed medicines such as corticosteroid, immunosuppressant, and biologic agents from the retail pharmacy at a faster pace. Additionally, retail pharmacies involve patient counseling, medication and health insurance information and management, which improves patient satisfaction and outcomes. Stakeholders use them to interface with the health systems and electronic health records, thereby providing continuity of care to patients with uveitis. Due to increased diversification of services and sophisticated patient and consumer focus in retail pharmacy, they significantly contribute to meeting the increasing needs of the market for uveitis medications and dominating the distribution of drugs.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest uveitis treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and the Middle East and Africa. According to the report, North America was the largest regional market for uveitis treatment.

As per the uveitis treatment market report, North America holds the largest market share due to its well-developed and advanced healthcare sector, acceptance of novel therapeutic management, and direct spending on research and development. As reported by the National Institutes of Health (NIH), a significant budget is devoted to autoimmune disease studies in the United States alone and there exists a conducive environment for numerous clinical trials and partnerships among various pharmaceutical entities, research institutions, and caregivers. Such strategic investment allows North American countries to take a frontline in the development and commercialization of biologics, immunomodulatory, and other approaches to treating uveitis. Also, presenting a higher frequency of autoimmune diseases which later develop into uveitis, the North American region needs efficient uveitis treatment and management, thereby carrying the market leadership of the global uveitis market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The uveitis treatment companies are focusing on the development of uveitis treatment include pharmaceutical companies and research institutions to meet the various challenges presented by the uveitis disease process through clinical trials. The market leaders such as AbbVie, Novartis, and Allergan are committed to research and development to launch new drugs that address specific immunological processes of uveitis development. For instance, the research strategies of AbbVie involve recent collaborations and clinical trials that explore the usage of biologics for autoimmune uveitis, proving the focus on precision medicine. Many of these activities are funded through government and research grants that promote academic-industry collaboration to advance therapeutic progress and improve patients' care in the context of the shifting uveitis treatment paradigm, thus fueling uveitis treatment industry growth.

Uveitis Treatment Market News:

In April 2024, Brepocitinib demonstrated positive results for treating non-infectious uveitis in a Phase 2 study, showing promising efficacy in reducing inflammation and improving patient outcomes.

Key Questions Answered in This Report

  • 1. What was the size of the global uveitis treatment market in 2023?
  • 2. What is the expected growth rate of the global uveitis treatment market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global uveitis treatment market?
  • 4. What are the key factors driving the global uveitis treatment market?
  • 5. What is the breakup of the global uveitis treatment market based on the treatment type?
  • 6. What is the breakup of the global uveitis treatment market based on the disease type?
  • 7. What is the breakup of the global uveitis treatment market based on the cause?
  • 8. What is the breakup of the global uveitis treatment market based on the distribution channel?
  • 9. What are the key regions in the global uveitis treatment market?
  • 10. Who are the key players/companies in the global uveitis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Uveitis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Monoclonal Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cycloplegic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Antivirals
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Antifungal
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Analgesics
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Anterior Uveitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Posterior Uveitis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intermediate Uveitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panuveitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cause

  • 8.1 Infectious
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-infectious
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alimera Sciences Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Enzo Biochem Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Eyegate Pharmaceuticals Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Eyepoint pharmaceuticals Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Regeneron Pharmaceuticals Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Santen Pharmaceutical Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2023
  • Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: China: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: India: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: France: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
  • Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
  • Figure 95: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million US$), 2024-2032
  • Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Uveitis Treatment Market Structure
  • Table 8: Global: Uveitis Treatment Market: Key Players